-Wearable medical robot device
-Previously unmet demand
-Targets 2021Q4 cash flow breakeven
-High risk, potentially high return
LD Micro and IR presentations provide a good overview.
Just reading up on $MYO CEO Paul Gudonis.
He led Genuity Inc since 1994 and its inception as part of BBN Corp, the firm that developed the precursor to today's internet.
Genuity grew from a regional network operator with $5m revenue to a $ bn global internet services firm...
..Gudonis took the co public in June 2000, raising nearly $2bn. As so many cash burning internet co's Genuity filed Chapter 11. In 2003, Level 3 eventually bought most of its assets.
Would this still be a reason to put a discount on $MYO ?
Mr Market is cheering on $MYO joint venture announcement in China.
Isn't MYO selling its capabalities way too cheaply?
19.9% JV interest for MYO
Partners to invest $8-20m
$2.5m upfront license fee
$10.75m minimum Myopro purchase commitment
$MYO videos show how the MyoPro empowers persons with a neuromuscular disability to perform functional activities at home, at work, and in the community.
-MyoPro gives back arm/hand function to people with paralysis
-Lare pool of people with previously unmet demand; 300k in US, globally close to 1m people
-Patent protection until well into 2030s
-Limited/no competition
..
-Growth is accelerating after
a) Covid pandemic made it difficult to meet new customers and fit the MyoPro device,
b) as new Direct marketing efforts ramp up, and
c) additional health insurers line up to reimburse
-Breakeven planned to be reached in 2021Q4 with ~$7m..
quarterly revenue. Gross margins are to expand to the 70-75% range thanks to the shift to 'Direct billing' with higher ASP (overall ASP ~38k).
-Outsourced production, providing asset-light growth
-Very reasonable EV/S for potentially 100%+ growth in 2021
Added to $MYO
Am I alone in seeing similarities with Semler Scientific $SMLR back in early 2017?
With the covid pandemic constraints ending, and great operating momentum at $MYO, I don't understand why sell-side estimates have not moved higher yet.
The sell side has not even reflected the $2.5m upfront license fee from Ryzur Medical.
1/2
Sales 2021E $11.8m
Guidance 2021Q4 $7.0m
Upfront license fee Ryzur $2.5m
Is $MYO really only going to do $2.3m in 'normal' revenue over the first 9 months of 2021?!
In 2020 MYO did a minimum of $0.9m per quarter despite huge covid headwinds.
Sales grew >100% in 2020Q4.
2/2
Sidoti estimates $11m revenue for $MYO in 2021. That just seems incredible easy to beat with 100%+ growth in 2020Q4, and the $2.5m upfront license fee coming in from Ryzur.
At least the price target was raised to $23 from $14.